TRIM55 Aggravates Cardiomyocyte Apoptosis After Myocardial Infarction via Modulation of the Nrf2/HO-1 Pathway

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2024-09-01 DOI:10.1016/j.jacbts.2024.05.006

Yuxin Bu MM , Yanxia Liu MD , Meili Liu MD, Chenghui Yan MD, Jing Wang MM, Hanlin Wu MM, Haixu Song MD, Dali Zhang MD, Kai Xu MD, Dan Liu MD, Yaling Han MD, PhD

{"title":"TRIM55 Aggravates Cardiomyocyte Apoptosis After Myocardial Infarction via Modulation of the Nrf2/HO-1 Pathway","authors":"Yuxin Bu MM , Yanxia Liu MD , Meili Liu MD, Chenghui Yan MD, Jing Wang MM, Hanlin Wu MM, Haixu Song MD, Dali Zhang MD, Kai Xu MD, Dan Liu MD, Yaling Han MD, PhD","doi":"10.1016/j.jacbts.2024.05.006","DOIUrl":null,"url":null,"abstract":"<div><div>Tripartite motif-containing 55 (Trim55) is mainly expressed in myocardium and skeletal muscle, which plays an important role in promoting the embryonic development of the mouse heart. We investigated the role of Trim55 in myocardial infarction and the associated molecular mechanisms. We studied both gain and loss of function in vivo and in vitro. The results showed that Trim55 knockout improved cardiac function and apoptosis after myocardial infarction, and overexpression aggravated cardiac function damage. The mechanism is that Trim55 interacts with nuclear factor, erythroid derived 2 (Nrf2) to accelerate its degradation and inhibit the expression of heme oxygenase 1, thereby promoting cardiomyocyte apoptosis.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 9","pages":"Pages 1104-1122"},"PeriodicalIF":8.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452302X24002134/pdfft?md5=017379718d1c2bd24f63c67d39e1d9dd&pid=1-s2.0-S2452302X24002134-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24002134","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Tripartite motif-containing 55 (Trim55) is mainly expressed in myocardium and skeletal muscle, which plays an important role in promoting the embryonic development of the mouse heart. We investigated the role of Trim55 in myocardial infarction and the associated molecular mechanisms. We studied both gain and loss of function in vivo and in vitro. The results showed that Trim55 knockout improved cardiac function and apoptosis after myocardial infarction, and overexpression aggravated cardiac function damage. The mechanism is that Trim55 interacts with nuclear factor, erythroid derived 2 (Nrf2) to accelerate its degradation and inhibit the expression of heme oxygenase 1, thereby promoting cardiomyocyte apoptosis.

查看原文本刊更多论文

TRIM55 通过调节 Nrf2/HO-1 通路加剧心肌梗死后的心肌细胞凋亡

含三方基序的 55（Trim55）主要在心肌和骨骼肌中表达，在促进小鼠心脏胚胎发育方面发挥着重要作用。我们研究了 Trim55 在心肌梗死中的作用及其相关分子机制。我们对体内和体外的功能增益和丧失进行了研究。结果表明，Trim55敲除可改善心肌梗死后的心功能和细胞凋亡，而过表达则会加重心功能损伤。其机制是Trim55与核因子红细胞衍生2（Nrf2）相互作用，加速其降解并抑制血红素加氧酶1的表达，从而促进心肌细胞凋亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.